At SABCS 2024, Professor Ian Kunkler presented the 10-year results of the SUPREMO trial, a phase III study evaluating the role of postmastectomy radiotherapy (PMRT) in intermediate-risk breast cancer. The trial aimed to determine whether PMRT improves overall survival in patients with 1-3 positive lymph nodes or high-risk node-negative disease.Key Takeaways
- No survival benefit—PMRT did not significantly improve 10-year overall survival.
- Minimal impact on local recurrence—a less than 2 percent reduction in chest wall recurrence was observed but lacked clinical significance.
- No effect on disease-free or metastasis-free survival, reinforcing the role of systemic therapy advancements in modern treatment.
- Personalized treatment is key—while PMRT may not be necessary for most intermediate-risk patients, certain high-risk subgroups may still benefit.
What This Means for Clinical Practice
With multidisciplinary care evolving, the role of PMRT in intermediate-risk breast cancer is being reconsidered. These findings emphasize a shift toward tailored treatment decisions, avoiding unnecessary radiation exposure in low-benefit cases while ensuring optimal care for high-risk patients.
Looking back at SABCS 2024, the SUPREMO trial results continue to shape discussions on refining postmastectomy treatment strategies.
A sincere thank you to Professor Ian Kunkler for leading this important research.
#Throwback #SABCS2024 #BreastCancer #Radiotherapy #OncologyResearch #ClinicalTrials #PersonalizedMedicine
